Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
johnhancoque, IF Denner is accumulating shares we wouldn't know it till his order is filled then Sarissa has 10 days after completion of his order to file the amended 13D. He could have started to accumulate shares a month ago but if he's out to own more than his current position without disrupting the market he can take his sweet time before he files with the SEC. Hope this helps.
Sleven, interesting twist of events. Thx
Sleven, more BS.
CCB, IF Brave top line results are positive, consider this scenario, the jocking around of Denners partner, Susan Langer, to be appointed to Biogens board and Biogens progress to get their alzheimers drug ins. coverage be a possible fit for a Vascepa acquisition ? Just saying.
LBL, good to hear from you. Hope your assumption is accurate! We need an uptick.
Hey meowzo, say whaaaaat?
Jasbg, I did not see your post till now. Wouldn't be wonderful if they actually answered a few shareholder's questions.
Tal, happened to be passing through and thought I'd share that Amarin has posted several positions on Linkedin which indicates they are moving forward with hiring in several countries.
The questions you proposed are so important for us uninformed shareholders who would love to hear the answers but I have little faith that they will go off script to answer any shareholder's concerns.
It's obvious they are struggling with EU acceptance and had NO idea what they were up against.
Geopolitical turmoil isn't helping the cause either.
sleven, fyi thanks for the heads up.
Today, Amarin congratulates its partner Edding Pharm on its first commercial sale of VASCEPA (icosapent ethyl) in Mainland China. This marks another important step in the effort to ensure access to this novel treatment for patients across that country. pic.twitter.com/94hAfPzkAK
— Amarin (@Amarincorp) October 10, 2023
Tal, Thanks for this amazing data. Unfortunately, I don't think this will move the needle for the price of the stock. Just another reason why everyone should be inhaling Vascepa.🙂
Tal, Once again you have posted another articulate message regarding the unknown AD tidbits. Actually, I'm shocked that others who have been on this board for many years didn't research Denner's success stories. It has been mentioned in many articles the level of his intelligence is unusually high.
On another note, the patent approval process of 22 months you reference would it happen to be for MND-2119?
Capt, as you know Denner is beyond qualified in chemistry. He knows the value of Vazkepa. Stay tuned.
Capt, What are your thoughts about the PR this AM? Do you think something positive is in the works to trigger this warning? Maybe another approval to cause this caveat to be included in side effects?
Zip/CBB, almost 2 years after Denner started buying AMRN I find it interesting that Denner added to his position. If you think about the logic for investing an additional $4.2mill in our company there is definitely more to the story other than the obvious. He didn't have to increase his holdings to gain additional control as he had won that battle with that item out of the way. Supporting the price over $1.00 may be a thought but he could have asked one of his buddies in the biotech arena to buy shares at this price BUT Denner sees additional value in Vascepa than we'll ever know about until it's publicly known.
Tal, he's putting his money where his mouth is---- kudos to AD. A sigh of relief can be heard from NJ to the EU et al.
http://archive.fast-edgar.com/20230905/AD2FL22CZZ22MTJ2229I2Z42AAS2ZC22N252
Seve333, when they start showing revenue growth from EU should spark some interest but until they have one or 2 qtrs of growing rev increases without an FDC it will be slow growth. Vascepa is too valuable to let it become shelfware. I'm guessing 2024 going into '25 something will materialize. I refuse to give up on my initial reason for investing in Amarin as the Capt would say "It's the EPA Stupid"
My interest started around 2018-19. I traded around my original investment and did well. Then 3/30/2020 hit and the rest is history. My optometrist recommended fish oil after cataract surgery. Couldn't tolerate the side effects of fish oil capsules then being a stock junky I heard about Vascepa and JT's pitch. After researching the company I asked my GP for a script she agreed given the heart issues in my family and my own high numbers so I've been taking V ever since. Honestly, I could feel the sense of well-being almost immediately. Several yrs later all my numbers across the board are where they should be and I'm 4 yrs older.🙂
Tal, there's still hope in 2024. For both Amarin and politics.
kash, I've been mia from Ihub, sorry my last post was incorrect but did read your reply to Tal. Still very interesting. Thx
Tal: I found the post you were asking about it's #414949. It's worth a read.
KashSmooth, I found your last post #414949 on your profile page. It wasn't deleted. The link posted about the Federalist was super informative and one of the most interesting I've read in a while. Thanks for the link.
Ramfan, my pleasure where's the tip tab?
ORBAPU, your post is one of the best descriptions of EPA in plain english I've read in a while.
If a person buys the stock it would be like shooting a fish in a barrel. It's a winner.🤣
I happen to come across this silly article in the WOPO BS newspaper. Stupid people are clueless. Sorry if this has already been hashed over by IHub posters.
Fish oil supplements don't have the same benefits fish do (gift article link) @washingtonpost https://t.co/wcwGa0KCN8
— Cheryl Iny Harris, MPH, RD (@CherylharrisRD) August 24, 2023
Kiwi, possibly, but it will take several qtrs before revenues from UK make and impact. We need another drug in the pipeline hence the FDC.
Tatsumaki, Your assumption about shorting between funds would only be legal if it's in their charter. I doubt "they" would trade between funds. It doesn't make sense I think it's for other reasons why the shares have been distributed to several funds. If Sarissa did a distribution between funds which he doesn't control he would have to report it. It boils down to "beneficial ownership". Also, a distribution between prime brokers is a wise decision on Sarissa's part since there's so much uncertainty regarding the stability of the financial institutions. If and when the shares do pop on a major news event they could be worth more than his other positions in various prime broker accounts.
The fact is the price of the shares won't gain Wall Street's attention unless Amarin reinvents itself with another drug or derivative thereof.
johnhancoque, don't try to replace my wording. You don't know what my feelings are...time to smash the ignore button!
Happen to search Amarin using X/Twitter. This is the most bizarre company description or lack thereof I've ever seen.
I have made a few attempts to contact IR or anyone for that matter of course NO replies. Very disturbing.
https://amarincorp.com/docs/AmarinSocialCommunityGuidelines.pdf
Thonn, maybe they ship to patients who live in an area where Vazkepa is not approved? Just sayin
Thonn, maybe the higher number is due to the fact that they have 2 locations with a focus on senior healthcare??
https://www.marshmedicalpractice.com/
caddiedad, what are you talking about in your post? I consider this a positive.
https://amarincorp.gcs-web.com/node/23636/html
newman, FYI yesterday's midday block trades were sell orders, approx 3mill. I tried to do a screenshot but no luck.
robin, this filing is an S8 filing and an update of several items which includes the issuance of 20 mill more authorized shares. It replaces approx 3.3mill which were cancelled and are prolly KM's shs and others who left the company. The company is required to update the shelf filing every 2 yrs. hope this helps.
https://www.sec.gov/Archives/edgar/data/897448/000119312523201194/d495386ds8.htm
https://www.investopedia.com/terms/s/sec-form-s-8.asp
Talk, my .02cents is they will go branded generic in US once MND-20119 is launched. Thinking out loud.
Sleven, thanks, that's very impressive findings.
Tal, I assume you meant to write Mochida? Yes? In your opinion, is the in-licensing agreement between Amarin and Mochida a plus for all involved?
Tal, thanks for follow up. The comments at the bottom of DOGN's post show the enthusiasm of a few shareholders re the combo pill. It will be a game changer.
ziploc, the agreement I found was dated 6/12/2018. Where did you find the 2015 agreement? Maybe there's another earlier agreement? Thx
A must read post from DOGN. Thx
So I asked the question where's the Mochida 6/12/2018 agreement and look what I found. A post #385729 from DOGN it's loaded with information. It does say Amarin has an exclusive licensing agreement outside of Japan for MND-2119.
ziploc, the agreement I found was dated 6/2/2018. Where did you find the 2015 agreement? Maybe there's another earlier agreement? Thx